Harrow, Inc. (HROW) Stock Analysis: 30% Upside Potential Amid Strong Buy RatingsHarrow, Inc. (NASDAQ: HROW) has been making waves in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With eight buy recommendations and no hold or sell ratings, Harrow is capturing the confidence of market analysts. Analysts have set a target price range of $42.00 to $76.00 for Harrow, with the average target pegged at $60.10. This reflects a potential upside of approximately 30.40% from its current price level, presenting a compelling opportunity for investors seeking exposure to the healthcare sector. Overall, Harrow, Inc. is an intriguing player in the eyecare pharmaceutical market, offering significant upside potential backed by strong analyst support and robust revenue growth.